These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9123156)

  • 1. Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1997; 29(1-2):617-9. PubMed ID: 9123156
    [No Abstract]   [Full Text] [Related]  

  • 2. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
    Pham SM; Kormos RL; Kawai A; Murali S; Hattler BG; Demetris AJ; Griffith BP
    Transplant Proc; 1996 Apr; 28(2):1002-4. PubMed ID: 8623208
    [No Abstract]   [Full Text] [Related]  

  • 3. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
    Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
    Adamson R; Obispo E; Dychter S; Dembitsky W; Moreno-Cabral R; Jaski B; Gordon J; Hoagland P; Moore K; King J; Andrews J; Rich M; Daily PO
    Transplant Proc; 1998 Jun; 30(4):1107-9. PubMed ID: 9636449
    [No Abstract]   [Full Text] [Related]  

  • 5. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
    Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
    Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of cyclosporine dose on long-term outcome after heart transplantation.
    Valantine H; Hunt S; Gamberg P; Miller J; Luikart H
    Transplant Proc; 1994 Oct; 26(5):2710-2. PubMed ID: 7940848
    [No Abstract]   [Full Text] [Related]  

  • 7. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
    Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
    Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
    Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
    Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
    [No Abstract]   [Full Text] [Related]  

  • 9. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group.
    Jensik SC
    Transplant Proc; 1998 Jun; 30(4):1216-8. PubMed ID: 9636494
    [No Abstract]   [Full Text] [Related]  

  • 10. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation.
    Taylor DO; Kfoury AG; Pisani B; Hammond EH; Renlund DG
    Transplant Proc; 1997 Dec; 29(8A):13S-15S. PubMed ID: 9414668
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody therapy in steroid-resistant rejection.
    Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
    [No Abstract]   [Full Text] [Related]  

  • 13. FK506 for primary and rescue therapy following liver transplantation.
    Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclosporine-based steroid-free therapy in pediatric heart transplantation: long-term results.
    Livi U; Caforio AL; Gambino A; Tursi V; Milanesi O; Stellin G; Angelini A; Casarotto D
    Transplant Proc; 1998 Aug; 30(5):1975-6. PubMed ID: 9723358
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 16. Usefulness of quantitative cytomegalovirus antigenemia determinations in heart transplantation.
    Manito N; Perez JL; Roca J; Castells E; Niubó J; Garcia A; Ribas M; Saura E; Rufí G; Gomez-Hospital JA; Espinoza C; Esplugas E
    Transplant Proc; 1999 Sep; 31(6):2526-7. PubMed ID: 10500700
    [No Abstract]   [Full Text] [Related]  

  • 17. Experience with azathioprine withdrawal after simultaneous kidney-pancreas transplantation.
    Stratta RJ
    Transplant Proc; 1998 Jun; 30(4):1353-4. PubMed ID: 9636550
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients.
    el-Ghoroury M; Hariharan S; Peddi VR; Munda R; Schroeder TJ; Demmy AM; Alexander JW; First MR
    Transplant Proc; 1997; 29(1-2):649-51. PubMed ID: 9123461
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute cardiac ongoing rejection: comparison between different strategies.
    Forni A; Faggian G; Luciani GB; Lamascese N; Mazzucco A
    Transplant Proc; 2001 May; 33(3):2395-7. PubMed ID: 11377573
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of various immunosuppressive regimes in second renal transplants.
    Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
    Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.